Exactech develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. The Company's operating segments are represented by its major product lines: knee implants, hip implants, biologics and spine, extremity implants and other products. Its other products segment includes miscellaneous sales categories, such as surgical instruments held for sale, bone cement, instrument rental fees, shipping charges, and other implant product lines.
The Company manufactures some components of its knee, extremity, and hip joint replacement systems at its facility in Gainesville, Florida. Its joint replacement products are used by orthopedic surgeons to repair or replace joints that have deteriorated as a result of injury or disease. Exactech's spinal implants are used as an adjunct to the fusion of vertebrae in the treatment of spinal disease and deformity.
Parent Company
Gainesville, US
Exactech was founded in 1985 and is headquartered in Gainesville, US

Exactech Office Locations

Exactech has offices in Gainesville, Capinghem, Bella Vista, Chūō-ku and in 10 other locations
Gainesville, US (HQ)
2320 NW 66 Ct
Bella Vista, AU
2 14 Lexington Dr
Capinghem, FR
Rue de la Zamin
La Tronche, FR
5 Avenue du Grand Sablon
Chūō-ku, JP
Bern, CH
5 Weltpoststrasse
Show all (14)

Exactech Financials and Metrics

Summary Metrics

Founding Date

Exactech is a subsidiary of TPG

Exactech Financials

Exactech's revenue was reported to be $257.6 m in FY, 2016
USDFY, 2013FY, 2014Y, 2015FY, 2016


237.1 m248.4 m241.8 m257.6 m

Revenue growth, %


Cost of goods sold

73 m74.2 m73.6 m80.3 m

Gross profit

164.1 m174.1 m168.2 m177.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


55.7 m63.3 m63.9 m57.9 m61.4 m61.5 m56.2 m65.3 m66.1 m59.9 m69.5 m67.3 m61.4 m

Cost of goods sold

16.1 m18.6 m19.6 m16.9 m18.6 m19.3 m16.6 m20.4 m20.3 m18.8 m20.6 m21.1 m18.2 m

Gross profit

39.5 m44.6 m44.4 m41 m42.7 m42.2 m39.6 m44.9 m45.9 m41.1 m48.8 m46.3 m43.2 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


6 m10.1 m12.7 m13.1 m

Accounts Receivable

59.1 m50.7 m52.4 m99.1 m


71.6 m72.8 m71.4 m65.3 m

Current Assets

142.6 m139.2 m141.4 m143.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


6.8 m11.3 m11 m9.1 m12.3 m14.9 m17.1 m9.1 m10.1 m12.6 m11.2 m8.9 m11.7 m

Current Assets

141.8 m136.9 m141 m135.9 m141.4 m145.7 m145.9 m140.9 m143.6 m144.7 m140.5 m142.2 m143 m


13.4 m13.5 m13.5 m13.2 m17.4 m19 m19.1 m22.6 m22.3 m22.5 m14.2 m14.8 m14.9 m

Total Assets

261.9 m255.8 m262.2 m257.9 m272.5 m274.5 m277.2 m290.7 m295.8 m300.1 m297.1 m301.8 m307.2 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    15.4 m16.5 m14.8 m162 k

    Depreciation and Amortization

    17.6 m18.5 m16.9 m18 m

    Accounts Receivable

    (11 m)6.4 m(3.1 m)(2.1 m)


    (9.7 m)(9.1 m)(6.9 m)(15.7 m)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    3.2 m4.2 m4.2 m3 m4.1 m3.7 m2.9 m4.4 m4.4 m3.2 m4.6 m2.9 m

    Depreciation and Amortization

    4 m4.3 m4.1 m4.3 m4.4 m4.2 m4.1 m4.3 m4.4 m4.6 m4.7 m

    Accounts Payable

    17.4 m15.6 m14.2 m13.3 m12.6 m17.1 m15.9 m14.1 m16.7 m18.3 m
      Show all financial metrics

      Exactech Revenue Breakdown

      Exactech's Web-traffic and Trends

      Exactech Online and Social Media Presence

      Exactech News and Updates

      TPG Capital and Exactech amend deal terms

      TPG Capital and Exactech have amended the details of their previously announced deal. According to the new terms, TPG Capital has agreed to acquire Exactech in a take-private buyout for $49.25 per share as opposed to the previously agreed amount of $42 per share. After the closing of the deal, Exact…

      Absolute Analysis on Corneal Transplant Market: CAGR of 8.5% By 2023

      Market Research Future published a research report on “Corneal Transplant Market Research Report - Global forecast till 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday

      TPG to acquire Exactech in take-private deal

      TPG Capital has agreed to acquire Exactech in a take-private buyout for $42 per share. After the closing of the deal, Exactech will no longer trade on the NASDAQ. J.P. Morgan Securities LLC is serving as financial adviser to Exactech on the transaction. Greenberg Traurig, P.A. (Miami) and Greenberg …

      Exactech Company Life and Culture

      You may also be interested in